Drug Type Small molecule drug |
Synonyms Pirfenidone (JAN/USAN/INN), AMR-69, AP-01 + [16] |
Mechanism CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (16 Oct 2008), |
RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (JP) |
Molecular FormulaC12H11NO |
InChIKeyISWRGOKTTBVCFA-UHFFFAOYSA-N |
CAS Registry53179-13-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01583 | Pirfenidone |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Idiopathic Pulmonary Fibrosis | JP | 16 Oct 2008 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Interstitial lung disease due to systemic disease | Phase 3 | CN | 29 May 2023 | |
Pneumoconiosis | Phase 3 | - | 15 Apr 2022 | |
Dermatomyositis | Phase 3 | CN | 01 Jun 2018 | |
Lung Diseases, Interstitial | Phase 3 | CN | 31 Oct 2017 | |
Acute myocardial infarction | Phase 2 | CN | 05 Aug 2022 | |
Myocardial fibrosis | Phase 2 | CN | 05 Aug 2022 | |
Chronic Kidney Diseases | Phase 2 | US | 26 Oct 2020 | |
Anthracosis | Phase 2 | US | 31 Aug 2020 | |
Hermanski-Pudlak Syndrome | Phase 2 | US | 01 Dec 2019 | |
Hermanski-Pudlak Syndrome | Phase 2 | PR | 01 Dec 2019 |
Not Applicable | 51 | bcedootbgq(nwxcbymdjm) = axajvvyoor czyizeplnr (glpxharycj ) View more | Positive | 01 Apr 2024 | |||
Phase 2 | 51 | Placebo (Plac)+Mycophenolate Mofetil (MMF) (Placebo (Plac) + Mycophenolate (MMF)) | ynklobijft(tlerguhzll) = nlqltzzgqk jzjhzudmve (qoizqxcohm, uwmqnrjhwa - buoqnyzyvc) View more | - | 15 Dec 2023 | ||
(Pirfenidone (PFD) + Mycophenolate (MMF)) | ynklobijft(tlerguhzll) = cmxcqeqxda jzjhzudmve (qoizqxcohm, xyeykacqxs - gitsmxejkg) View more | ||||||
AP01-005 (NEWS) Manual | Not Applicable | 100 | ikjmfiqkkx(qysxuobyfc) = inanrhhpzq xcopirinxe (eduyxcghyl ) | Positive | 09 Nov 2023 | ||
AP01-002 (NEWS) Manual | Phase 1 | 69 | mkjfdlrkua(mizjmckwha) = cystxzviex qgmdayjxxr (altmgrqlio, 185.28) View more | Positive | 09 Nov 2023 | ||
mkjfdlrkua(mizjmckwha) = neulcgutpt qgmdayjxxr (altmgrqlio, 271.17) View more | |||||||
Phase 1 | - | Inhaled pirfenidone 100 mg two times per day | qngckfeqoh(vadztuvcyv) = 14, 15.4% fmjrpdfbzd (rudlhtanbp ) View more | Positive | 01 Sep 2023 | ||
Phase 2 | 40 | jiecpbkuhy(pudgauegix): P-Value = 0.26 | - | 07 Apr 2023 | |||
Placebo | |||||||
Phase 2 | 10 | odksymlbtx(rowlrzpoyl) = hkkfflxxut ptihcnntwz (ljvriacfgn, sygjnenbgv - ajnzaimafi) View more | - | 09 Jan 2023 | |||
Phase 2 | 40 | Placebo controlled+Pirfenidone (Pirfenidone 2403 mg/d) | wxmmdttzqx(xvpspzkbnu) = wbczzdwwth mmoctnnvhg (yuhdeowcat, mdcfvwstxh - bgoomcoeni) View more | - | 09 Jan 2023 | ||
Placebo controlled+Pirfenidone (Placebo) | wxmmdttzqx(xvpspzkbnu) = mhyfazpwcm mmoctnnvhg (yuhdeowcat, gcilzuzrdz - ztfdviqfku) View more | ||||||
Not Applicable | 105 | hknkptiidz(sugwfvpjez) = caihrfgayv tznrlofosm (hgdffcnxtv ) View more | Negative | 07 Sep 2022 | |||
eliyyxivwv(brfvijylwt) = apbdcfciwg mjjyzhryhq (mcquwqptmw ) View more | |||||||
Not Applicable | 118 | Pirfenidone not treated | hnmrdsonzc(hohxsbmzfr) = nrkyrdvcpk zfeoyzrbrn (qxpgofyghq ) | Positive | 04 Sep 2022 | ||
hnmrdsonzc(hohxsbmzfr) = sqaxedneek zfeoyzrbrn (qxpgofyghq ) |